125I放射性粒子治疗复发性腮腺癌24例临床分析

目的 探讨应用¹²⁵I放射性粒子组织间植入近距离放疗在腮腺区复发恶性肿瘤的临床应用及疗效。方法 回顾性分析2006年至2013年，就诊于北京大学口腔医院，经放射性¹²⁵I粒子组织间植入治疗的24例复发腮腺腺源性恶性肿瘤患者的临床资料，所有患者均为临床Ⅳ期。定期随访，观察并分析局部控制率，生存率及不良反应。结果 24例复发肿瘤患者，随访时间4至59个月。6例局部控制失败，10例患者死亡。患者1年、3年生存率分别为74.8%和39.3%，1年、3年无进展生存率分别为74.8%和31.5%，1年、3年局部控制率分别为82.0%和69.4%。无3级以上放射性损伤。结论 单纯放射性¹²⁵I粒子组织间植入治疗，对于无法手术切除的复发腮腺恶性肿瘤患者，为可选治疗方式，局部控制率较好。

Clinical analysis of 125I brachytherapy alone for 24 recurrent parotid gland carcinoma

Objective To evaluate the efficacy of ¹²⁵I brachytherapy alone for the treatment of recurrent parotid gland carcinoma. Methods Recurrent parotid gland carcinoma patients (n=24) treated by ¹²⁵I brachytherapy alone between 2006 and 2013 at Peking University Hospital of Stomatology were enrolled in this retrospective study.All patients underwent surgery or radiotherapy.The local control rate,survival rate,and side effects were evaluated. Results The median follow-up time was 21 months (range,4-59 months).Among the 24 patients,6 had local failure and 10 died during the follow-up period.The 1-and 3-year overall survival rates,progression-free survival rates,local control rates were 74.8% and 39.3%,74.8% and 31.5%,82.0% and 69.4%,respectively.No grade 3 or over radiation injury was found. Conclusions ¹²⁵I seed brachytherapy alone could provide an alternative treatment method for inoperable recurrent parotid gland carcinoma patients.